作者: Blumenkranz, Mark S ; Williams, George A ; Drenser, Kimberly A ; Harper, Clio Armitage ; Wood, Edward H ; Hartnett, M Elizabeth ; Moshfeghi, Darius M ; Capone, Antonio ; Sieving, Paul A

Michael T. Trese, MD (1946–2022), a vitreoretinal surgeon, made significant contributions to the field of retina. Although most known for his work in pediatric retina surgery, he was a pioneer in areas such as medical retina, translational research, and telemedicine. This article reviews his major contributions to spread his knowledge more widely to vitreoretinal trainees and specialists. We discuss six areas where Trese made a lasting impact: lens-sparing vitrectomy, familial exudative vitreoretinopathy, congenital X-linked retinoschisis, autologous plasmin enzyme, regenerative medicine, and telemedicine. [ Ophthalmic Surg Lasers Imaging Retina 2023;54:701–712.]

2013-02-01·Retina (Philadelphia, Pa.)2区 · 医学

MICROPLASMIN (OCRIPLASMIN) IN PEDIATRIC VITREORETINAL SURGERY

2区 · 医学

Review

作者: Wong, S Chien ; Capone, Antonio

PURPOSE:

To discuss the potential role of microplasmin (ocriplasmin) as a surgical adjunct to vitrectomy in pediatric vitreoretinopathies.

METHODS:

Literature review of the laboratory and clinical evidence to date for the use of both autologous plasmin enzyme as an adjunct to vitrectomy and more recently recombinant microplasmin (ocriplasmin) as monotherapy for focal vitreomacular traction in adults.

RESULTS:

Autologous plasmin enzyme is currently being used as a surgical adjunct to vitrectomy, with supporting Levels 2 and 3 published evidence in a range of pediatric vitreoretinopathies including Stage 5 retinopathy of prematurity and congenital X-linked retinoschisis. The availability of autologous plasmin enzyme is limited. In recent Phase 3 clinical trials, intravitreal ocriplasmin versus sham injection resulted in resolution of focal vitreomacular traction in 27% versus 10% (P < 0.001, n = 652).

CONCLUSION:

Ocriplasmin may potentially be used as a surgical adjunct to vitrectomy in place of autologous plasmin enzyme. A Phase 2, randomized, placebo-controlled surgical trial is under way to assess this.

2011-08-01·American journal of ophthalmology

Intravitreal Injection of Autologous Plasmin Enzyme for Macular Edema Associated With Branch Retinal Vein Occlusion

Letter

作者: Patricia Udaondo ; Maria Garcia-Pous ; Manuel Díaz-Llopis ; Salvador Garcia-Delpech ; David Salom

100 项与纤溶酶相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脑梗塞	中国	吉林津升制药有限公司	2003-05-22
血栓闭塞性血管炎	中国	北京赛升药业股份有限公司	1999-01-01
血栓性脑梗塞	中国	北京赛升药业股份有限公司	1999-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


PA022 (AAO2008)	N/A	糖尿病性黄斑水肿	-	Intravitreal Plasmin	夢廠窪膚壓鏇鬱蓋淵醖(蓋醖獵網壓窪網憲網鬱) = 廠鬱鬱憲餘衊繭衊範製鏇夢憲簾觸築願醖網壓 (製簾齋齋鏇觸選壓膚膚, 0.24) 更多	积极	2008-11-09
ARVO2005	N/A	糖尿病性黄斑水肿	8	Autologous Plasmin Injection	繭餘壓鏇願鹹鏇獵獵窪(鏇遞選壓範艱淵壓鏇鏇) = mild inflammation was observed in one patient injected with 2.0 IU of plasmin, but the inflammation was resolved within 3 days 淵壓窪簾蓋壓選鹹齋鹹 (鑰壓顧衊構艱顧衊廠糧 ) 更多	积极	2005-05-01
AAO2000	N/A	糖尿病性视网膜病变	-	Autologous Plasmin Enzyme (APE)	鹹衊製壓鬱壓網衊構窪(夢獵繭廠構衊糧積範衊) = 襯廠鏇齋製餘糧積鬱夢窪積積壓齋鬱糧鬱鑰選 (齋鹽製範夢範廠鑰蓋襯 )	积极	2000-10-23
AAO2000	N/A	糖尿病性视网膜病变	-	Autologous Plasmin Enzyme	鹹衊製壓鬱壓網衊構窪(夢獵繭廠構衊糧積範衊) = 觸觸膚鹽餘遞積齋鬱簾窪積積壓齋鬱糧鬱鑰選 (齋鹽製範夢範廠鑰蓋襯 )	积极	2000-10-23